JNSW10032

JNSW10032 is an orally bioavailable small molecule inhibitor of the Menin-KMT2A (formerly Menin-MLL) protein-protein interaction. It is a derivative of oridonin, a natural diterpenoid isolated from the traditional Chinese medicinal herb *Rabdosia rubescens*. Developed by Qiuwen Biotechnology, JNSW10032 is being investigated for the treatment of acute myeloid leukemia (AML), particularly in patients with KMT2A rearrangements or NPM1 mutations. By disrupting the binding of Menin to KMT2A fusion proteins, the drug inhibits the expression of downstream leukemogenic genes such as HOXA9 and MEIS1, thereby promoting cell cycle arrest and differentiation of leukemic blasts. JNSW10032 is currently undergoing Phase I clinical evaluation in China for relapsed or refractory AML.